Commonly prescribed anti-depressants appear to be doing patients more harm than good, say researchers who have published a paper examining the impact of the medications on the entire body.
“It’s important because millions of people are prescribed anti-depressants each year, and the conventional wisdom about these drugs is that they’re safe and effective.”
“We need to be much more cautious about the widespread use of these drugs,” says Paul Andrews, an evolutionary biologist at McMaster University and lead author of the article, published today in the online journal Frontiers in Psychology.
Andrews and his colleagues examined previous patient studies into the effects of anti-depressants and determined that the benefits of most anti-depressants, even taken at their best, compare poorly to the risks, which include premature death in elderly patients.
Anti-depressants are designed to relieve the symptoms of depression by increasing the levels of serotonin in the brain, where it regulates mood. The vast majority of serotonin that the body produces, though, is used for other purposes, including digestion, forming blood clots at wound sites, reproduction and development.
What the researchers found is that anti-depressants have negative health effects on all processes normally regulated by serotonin.
The findings include these elevated risks:
developmental problems in infants
problems with sexual stimulation and function and sperm development in adults
digestive problems such as diarrhea, constipation, indigestion and bloating
A new blood test diagnoses major depression in teens—an approach that offers an objective diagnosis by measuring a specific set of genetic markers.
The current method of diagnosing depression is subjective. It relies on the patient’s ability to recount his or her symptoms and the physician’s ability and training to interpret them.
Diagnosing teens is an urgent concern because they are highly vulnerable to depression and difficult to accurately diagnose due to normal mood changes during this age period.
The test also is the first to identify subtypes of depression. It distinguished between teens with major depression and those with major depression combined with anxiety disorder. This is the first evidence that it’s possible to diagnose subtypes of depression from blood, raising the hope for tailoring care to the different types.
“Right now depression is treated with a blunt instrument,” says Eva Redei, a professor of psychiatry and behavioral sciences at Northwestern University Feinberg School of Medicine and lead investigator of the study, published in Translational Psychiatry.
“It’s like treating type 1 diabetes and type 2 diabetes exactly the same way. We need to do better for these kids.
“This is the first significant step for us to understand which treatment will be most effective for an individual patient,” adds Redei. “Without an objective diagnosis, it’s very difficult to make that assessment. The early diagnosis and specific classification of early major depression could lead to a larger repertoire of more effective treatments and enhanced individualized care.” [continue reading…]
A five year study conducted with thousands of local teenagers by University of Montreal researchers reveals that those who used speed (meth/ampthetamine) or ecstasy (MDMA) at fifteen or sixteen years of age were significantly more likely to suffer elevated depressive symptoms the following year. “Our findings are consistent with other human and animal studies that suggest long-term negative influences of synthetic drug use,” said co-author Frédéric N. Brière of the School Environment Research Group at the University of Montreal. “Our results reveal that recreational MDMA and meth/amphetamine use places typically developing secondary school students at greater risk of experiencing depressive symptoms.” Ecstasy and speed-using grade ten students were respectively 1.7 and 1.6 times more likely to be depressed by the time they reached grade eleven. [continue reading…]
This morning a posted a wonderful short film of Lord Philip Gould sharing his thoughts about his approaching death during the final weeks of his life.
I participate in Google+ where I have been excited and stimulated by things that are shared, the great conversations and connections I make.
My post on Philip Gould encouraged +Chris Holly to point me in the direction of a film called Griefwalker.
This documentary introduces us to Stephen Jenkinson, the leader of a palliative care counselling team at Toronto’s Mount Sinai Hospital. Through his daytime job, he has been at the deathbed of well over 1,000 people. What he sees over and over, he says, is “a wretched anxiety and an existential terror” even when there is no pain. Indicting the practice of palliative care itself, he has made it his life’s mission to change the way we die – to turn the act of dying from denial and resistance into an essential part of life.
This is a thought provoking documentary on a charismatic spiritual man. It will take several viewings to fully absorb the nuances of the film. There is the powerful recounting of Stephens encounter with parents whose daughter is dying, and how he helped guide them to accept and experience her death in a non-clinical and real way. It was very moving.
Take the time to watch this film I think you’ll find it worth it.
A new blood test diagnoses major depression in teens—an approach that offers an objective diagnosis by measuring a specific set of genetic markers.
